A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
03 02 2023
03 02 2023
Historique:
received:
06
05
2022
revised:
16
09
2022
accepted:
23
11
2022
pubmed:
1
12
2022
medline:
7
2
2023
entrez:
30
11
2022
Statut:
ppublish
Résumé
Unfortunately, available liver cancer treatments are associated with modest survival advantage. The biggest factor improving survival is early detection, but the current understanding of early transformation events is limited. Therefore, we set up a model to study these early events and investigated the relationship of premalignant, senescent hepatocytes, a regenerative environment, and the influence of secreted factors on liver tumorigenesis. Oncogene-induced senescence (OIS) was triggered in a subset of mouse hepatocytes, which under normal conditions, are eliminated by immunosurveillance. Inducing liver damage and regeneration was sufficient to trigger immunosurveillance escape of OIS hepatocytes, resulting in premalignant to malignant transformation and hepatocellular tumor development. Trefoil factor 3 (TFF3) was found to be overexpressed in OIS hepatocytes and in hepatocellular carcinoma. TFF3 deficiency strongly attenuated malignant transformation by increasing insulin-like growth factor binding protein 5 (IGFBP5) expression, which consequently dampened IGF receptor signaling. Furthermore, analysis of precancerous liver tissue validated TFF3 as an early liver cancer biomarker. Altogether, these findings provide mechanistic insights into early transformation and immunosurveillance escape in liver cancer, revealing TFF3 and IGFBP5 to be important players with opposite roles in tumorigenesis. Liver damage induces a compensatory regenerative response that can drive premalignant to malignant transformation of senescent hepatocytes.
Identifiants
pubmed: 36449018
pii: 711342
doi: 10.1158/0008-5472.CAN-22-1477
pmc: PMC9896023
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
428-440Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
Cell. 2020 Oct 15;183(2):377-394.e21
pubmed: 32976798
Mol Biol Cell. 2007 Nov;18(11):4543-52
pubmed: 17804819
Nat Med. 2002 Oct;8(10):1089-97
pubmed: 12219085
Biochem J. 2006 Apr 1;395(1):1-19
pubmed: 16526944
Nature. 2018 Jan 4;553(7686):96-100
pubmed: 29258294
Gene Ther. 1999 Jul;6(7):1258-66
pubmed: 10455434
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
Nat Rev Cancer. 2010 Jan;10(1):51-7
pubmed: 20029423
Nature. 2005 Aug 4;436(7051):642
pubmed: 16079833
BMC Cancer. 2009 Apr 03;9:103
pubmed: 19341485
Front Endocrinol (Lausanne). 2018 Feb 20;9:53
pubmed: 29515523
Biochim Biophys Acta. 2009 Nov;1793(11):1623-33
pubmed: 19665497
Trends Cancer. 2020 Oct;6(10):838-857
pubmed: 32482536
Hepatology. 2014 Nov;60(5):1767-75
pubmed: 24839253
Nat Cell Biol. 2013 Aug;15(8):978-90
pubmed: 23770676
Nature. 2011 Nov 09;479(7374):547-51
pubmed: 22080947
Nature. 2005 Aug 4;436(7051):720-4
pubmed: 16079850
J Hepatol. 2016 Jun;64(6):1403-15
pubmed: 26867490
Endocr Rev. 1999 Dec;20(6):761-87
pubmed: 10605625
Cancer Cell. 2018 Apr 9;33(4):785
pubmed: 29634951
Cell Res. 2018 Jul;28(7):775-778
pubmed: 29872106
Am J Surg Pathol. 1998 Sep;22(9):1125-31
pubmed: 9737246
Cell Cycle. 2012 Feb 15;11(4):730-9
pubmed: 22374671
Nat Protoc. 2008;3(7):1167-70
pubmed: 18600221
Clin Chim Acta. 2008 Sep;395(1-2):19-26
pubmed: 18538135
Nature. 2005 Aug 4;436(7051):725-30
pubmed: 16079851
Hepatology. 2014 Jul;60(1):349-61
pubmed: 24711261
Genes Dev. 2014 Jan 15;28(2):99-114
pubmed: 24449267
Mol Biol Rep. 2010 Dec;37(8):3813-8
pubmed: 20229017
Sci Rep. 2016 Dec 23;6:39334
pubmed: 28008951
Chin J Cancer. 2012 Jun;31(6):266-80
pubmed: 22313597
Nature. 2005 Aug 4;436(7051):660-5
pubmed: 16079837
J Hepatol. 2010 Nov;53(5):950-61
pubmed: 20739078
Mol Cancer Ther. 2002 Apr;1(6):405-15
pubmed: 12477053
J Pathol. 2002 Aug;197(5):582-8
pubmed: 12210076
Circ Res. 2004 Mar 19;94(5):E46-54
pubmed: 15001525